E-LIB Suche - Ergebnisse für: Algazi, Alain

1

Treatment Modality Impact on Patient‐Reported Quality of Li..:

Plonowska‐Hirschfeld, Karolina A. ; Gulati, Arushi ; Stephens, Erika M....
The Laryngoscope. 134 (2023) 4 - p. 1687-1695 , 2023

Link: https://doi.org/10.1002/..

2

Efficacy and safety of pembrolizumab monotherapy in patient..:

Oh, Do‐Youn ; Algazi, Alain ; Capdevila, Jaume...
Cancer. 129 (2023) 8 - p. 1195-1204 , 2023

Link: https://doi.org/10.1002/..

3

Amplification of the CXCR3/CXCL9 axis via intratumoral elec..:

Lee, Jack Y. ; Nguyen, Bianca ; Mukhopadhyay, Anandaroop...
Molecular Therapy - Oncolytics. 25 (2022) - p. 174-188 , 2022

Link: https://doi.org/10.1016/..

4

Safety and Efficacy of MEDI0457 plus Durvalumab in Patients..:

Aggarwal, Charu ; Saba, Nabil F. ; Algazi, Alain...
Clinical Cancer Research. 29 (2022) 3 - p. 560-570 , 2022

Link: https://doi.org/10.1158/..

5

Author Correction: PD-L1 blockade in combination with inhib..:

Ribas, Antoni ; Algazi, Alain ; Ascierto, Paolo A....
Nature Communications. 12 (2021) 1 - p. , 2021

Link: https://doi.org/10.1038/..

6

Safety and Efficacy of Pembrolizumab in Combination with Ac..:

Taylor, Matthew H. ; Betts, Courtney B. ; Maloney, Lauren...
Clinical Cancer Research. 28 (2021) 5 - p. 903-914 , 2021

Link: https://doi.org/10.1158/..

7

PD-L1 blockade in combination with inhibition of MAPK oncog..:

Ribas, Antoni ; Algazi, Alain ; Ascierto, Paolo A....
Nature Communications. 11 (2020) 1 - p. , 2020

Link: https://doi.org/10.1038/..

8

High response rate to PD-1 blockade in desmoplastic melanom..:

Eroglu, Zeynep ; Zaretsky, Jesse M. ; Hu-Lieskovan, Siwen...
Nature. 553 (2018) 7688 - p. 347-350 , 2018

Link: https://doi.org/10.1038/..

9

(P069) Prognostic Factors for Recurrence and Survival Indep..:

Xu, Melody J. ; Garsa, Adam A. ; Lazar, Ann...
International Journal of Radiation Oncology*Biology*Physics. 98 (2017) 2 - p. E33-E34 , 2017

Link: https://doi.org/10.1016/..

10

Durable treatment of ameloblastoma with single agent BRAFi ..:

Faden, Daniel L. ; Algazi, Alain
JNCI: Journal of the National Cancer Institute. 109 (2016) 1 - p. , 2016

Link: https://doi.org/10.1093/..

11

The Hippo effector YAP promotes resistance to RAF- and MEK-..:

Lin, Luping ; Sabnis, Amit J ; Chan, Elton...
Nature Genetics. 47 (2015) 3 - p. 250-256 , 2015

Link: https://doi.org/10.1038/..

12

Intratumoral electroporation of plasmid interleukin-12: eff..:

Daud, Adil ; Algazi, Alain ; Ashworth, Michelle...
Journal of Translational Medicine. 13 (2015) S1 - p. , 2015

Link: https://doi.org/10.1186/..

13

Comparative profile of cutaneous adverse events: BRAF/MEK i..:

Sanlorenzo, Martina ; Choudhry, Aditi ; Vujic, Igor...
Journal of the American Academy of Dermatology. 71 (2014) 6 - p. 1102-1109.e1 , 2014

Link: https://doi.org/10.1016/..

14

Treatment of cutaneous melanoma: current approaches and fut..:

Daud, Adil ; Algazi, Alain ; Soon, Chris
Cancer Management and Research. , 2010

Link: https://doi.org/10.2147/..

15

Detailed analysis of immunologic effects of the cytotoxic T..:

Comin-Anduix, Begoña ; Lee, Yohan ; Jalil, Jason...
Journal of Translational Medicine. 6 (2008) 1 - p. , 2008

Link: https://doi.org/10.1186/..